Combined IKZF1 and IG markers as new tools for diagnosis and minimal residual disease assessment in Tunisian B-ALL.
Bull Cancer
; 103(10): 822-828, 2016 Oct.
Article
en En
| MEDLINE
| ID: mdl-27614734
ABSTRACT
INTRODUCTION:
The monitoring of minimal residual disease (MRD) approach in patients diagnosed with B-acute lymphoblastic leukemia (B-ALL) allows an early detection of residual clones inducing relapses and therefore appropriate therapy strategy. The molecular markers may identify and quantify the residual blasts in B-ALL with normal cytology. In this study, we aimed to use combined IKZF1, IGH and IGK immunoglobulin genes for diagnosis and MRD monitoring in B-ALL sample using MLPA, multiplex PCR and real-time quantitative PCR.MATERIAL:
We showed that multiplex PCR and MLPA are necessary and complementary to detect IKZF1 deletions.RESULTS:
We have identified at the diagnosis clonal IGH rearrangement (VH3-JH5) and IKZF1 deletion (Δ4-7), which we have used it for MRD evaluation after induction chemotherapy. Despite the absence of chromosome abnormality, the patient may be classified in high-risk group with a relapse rate of residual blasts>10-4 and sensitivity up to 10-5. This molecular approach enabled the patient's stratification, which was overlooked by classical methods.CONCLUSION:
The combined IKZF1 and immunoglobulin genes will be used as appropriate molecular tools for diagnosis and MRD assessment of B-lineage leukemias and introduced as a routine tests in Tunisian clinical laboratories. They will be useful to stratify patients into risk groups leading to better treatment strategy.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Genes de Inmunoglobulinas
/
Leucemia-Linfoma Linfoblástico de Células Precursoras B
/
Cadenas Pesadas de Inmunoglobulina
/
Cadenas Ligeras de Inmunoglobulina
/
Eliminación de Gen
/
Factor de Transcripción Ikaros
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
/
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
Bull Cancer
Año:
2016
Tipo del documento:
Article
País de afiliación:
Túnez